Medicare reimbursement for investigational device exemptions (IDE) hangs fire
This article was originally published in Clinica
Just when it looks like the matter of Medicare reimbursement for use of unapproved devices has been settled, the Senate Finance Committee has begun making inquiries into such payments. This is apparently the latest round in a dispute which began when the Department of Health & Human Services Inspector General and Department of Justice investigated major hospitals' billing for use of unapproved drugs, currently forbidden under Medicare rules.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.